MaxCyte (MXCT) said Wednesday it is licensing its cell-engineering technology to TG Therapeutics (TGTX).
Financial terms were not disclosed.
Under the terms of the agreement, TG Therapeutics will gain non-exclusive research, clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte will receive annual licensing fees and other revenue, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.